Cited 14 time in
Coagulase-negative staphylococcal bacteremia: risk factors for mortality and impact of initial appropriate antimicrobial therapy on outcome
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Park, S. Y. | - |
| dc.contributor.author | Kwon, K. H. | - |
| dc.contributor.author | Chung, J. -W. | - |
| dc.contributor.author | Huh, H. J. | - |
| dc.contributor.author | Chae, S. L. | - |
| dc.date.accessioned | 2024-08-08T03:31:14Z | - |
| dc.date.available | 2024-08-08T03:31:14Z | - |
| dc.date.issued | 2015-07 | - |
| dc.identifier.issn | 0934-9723 | - |
| dc.identifier.issn | 1435-4373 | - |
| dc.identifier.uri | https://scholarworks.dongguk.edu/handle/sw.dongguk/17163 | - |
| dc.description.abstract | It is uncertain whether an initial inappropriate empirical antibiotic treatment of coagulase-negative staphylococci (CoNS) bacteremia adversely affects the outcome. A retrospective cohort study of CoNS bacteremia was performed at the Dongguk University Ilsan Hospital during a 3-year period. During the study period, 109 patients with CoNS bacteremia were enrolled. The median age of the patients was 72 years and most (96 %, 105/109) had one or more comorbid diseases. Among the participants, 29 % (32/109) received an appropriate empirical antimicrobial therapy. The 30-day mortality was 24 % (26/109) and CoNS bacteremia-related mortality was 14 % (15/109). There was no difference in the CoNS bacteremia-related mortality between the group with an inappropriate empirical treatment (13 %, 10/77) and that with an appropriate treatment (16 %, 5/32) (p = 0.46). In the multivariate analysis using the Cox regression analysis method, Pitt bacteremia scores [hazard ratio (HR) 1.48; 95 % confidence interval (CI) 1.09-2.01; p = 0.01] and retention of eradicable focus (HR 5.0; 95 % CI 1.39-17.9; p = 0.01) were found to be associated with CoNS bacteremia-related mortality. The results suggest that inappropriate empirical therapy might not necessarily be associated with the 30-day mortality or CoNS bacteremia-related mortality. Conversely, Pitt bacteremia scores and retention of eradicable focus were associated with poor outcomes. | - |
| dc.format.extent | 7 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | SPRINGER | - |
| dc.title | Coagulase-negative staphylococcal bacteremia: risk factors for mortality and impact of initial appropriate antimicrobial therapy on outcome | - |
| dc.type | Article | - |
| dc.publisher.location | 미국 | - |
| dc.identifier.doi | 10.1007/s10096-015-2364-3 | - |
| dc.identifier.scopusid | 2-s2.0-84931560934 | - |
| dc.identifier.wosid | 000356527200015 | - |
| dc.identifier.bibliographicCitation | EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, v.34, no.7, pp 1395 - 1401 | - |
| dc.citation.title | EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES | - |
| dc.citation.volume | 34 | - |
| dc.citation.number | 7 | - |
| dc.citation.startPage | 1395 | - |
| dc.citation.endPage | 1401 | - |
| dc.type.docType | Article | - |
| dc.description.isOpenAccess | N | - |
| dc.description.journalRegisteredClass | sci | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.relation.journalResearchArea | Infectious Diseases | - |
| dc.relation.journalResearchArea | Microbiology | - |
| dc.relation.journalWebOfScienceCategory | Infectious Diseases | - |
| dc.relation.journalWebOfScienceCategory | Microbiology | - |
| dc.subject.keywordPlus | BLOOD-STREAM INFECTIONS | - |
| dc.subject.keywordPlus | AUREUS BACTEREMIA | - |
| dc.subject.keywordPlus | HOSPITAL STAY | - |
| dc.subject.keywordPlus | CATHETER | - |
| dc.subject.keywordPlus | MANAGEMENT | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
30, Pildong-ro 1-gil, Jung-gu, Seoul, 04620, Republic of Korea+82-2-2260-3114
Copyright(c) 2023 DONGGUK UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
